OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Cancers & treatments·Sequencing

Non-metastatic castration-resistant prostate cancer: lines of therapy

Cancer page →

3 standard-of-care settings across 2 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersCastration-resistant
Screening, prevention and diagnosis1·
Early / localised·2

Screening, prevention and diagnosis

SubgroupSettingApproachProducts and trialsEvidence
All comersStagingPSMA PET locates disease in most men; conventional imaging still defines the setting the trials studied.
PSMA PETmCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)
96

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
Castration-resistantHigh-risk nmCRPC (doubling time 10 months or less)Continue androgen deprivation and add apalutamide (SPARTAN), enzalutamide (PROSPER) or darolutamide (ARAMIS); darolutamide preferred when falls or cognition are concerns.
ApalutamideEnzalutamideDarolutamideAndrogen deprivation & AR pathway inhibitorsCastration-resistant prostate cancer (CRPC)
95
Castration-resistantLow-risk nmCRPCObservation on androgen deprivation with PSA monitoring and imaging; first-generation antiandrogen or its withdrawal as older options.
Androgen deprivation & AR pathway inhibitorsBicalutamidePSA (prostate-specific antigen)
95

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.